REPOST:
***THE CASE FOR UEEC / FDA APPROVAL / JOHNSON & JOHNSON AND HEMOSTYP***
UEEC--We are highlighting this company as a speculative, yet heavily centric risk/reward play, with a very short turnaround. UEEC is awaiting PMA approval from the FDA, which was originally scheduled to be released 10/31. PMA approval could literally come any day at this point.
CURRENT STOCK PRICE: $1.19
52 WEEK LOW: $.51 CENTS
52 WEEK HIGH: $1.90
***OTC PINK CURRENT***
AUTHORIZED SHARES: 300,000,000
OUSTANDING SHARES: 188,513,000
FLOAT: 100,000,000
ABOUT HEMOSTYP:
HemoStyp Hemostatic Gauze is a flexible, cloth-like material that is applied by folding the gauze as needed to fit the size of the wound or incision, and then placing the gauze onto the bleeding tissue. In surgical situations, the product quickly converts to a transparent gel with a neutral pH level that allows the surgeon to monitor the coagulation process and also avoids damage to the surrounding tissue. In superficial wound situations, HemoStyp can be integrated into a plastic bandage with or without a traditional gauze component to help stop bleeding.
Potential Target Markets
Our technology can be marketed as HemoStyp Gauze in various configurations and sizes both domestically and internationally. Our potential customer base includes, without limitation, the following (noting that we have several formats of Trauma Gauze):
Hospitals and Surgery Centers for all Internal Surgical usage, post FDA Class III approval
•
Hospitals, Clinics and Urgent Care centers – For external trauma
•
EMS, Fire Departments and other First Responders
•
Correctional Facilities
•
Schools, Universities and Day Care Facilities
•
Nursing Homes and Assisted Living Environments
•
Home Care Providers
•
Dentist and OMS offices
•
Sports Medicine Providers
•
Veterinary hospitals
•
Municipalities and Government Agencies
•
Hemodialysis centers
Consumers
MARKET POTENTIAL:
The Class III surgical markets, both domestic and international, represent the most attractive market for our products due to the limited competition from other Class III approved hemostatic agents and the resulting premium pricing for products that can meet the demanding requirements of the human surgical environment. Our preliminary tests and our completed human trial lead us to believe that the HemoStyp technology can compete against established market participants and allow us to gain a significant market share. In 2018, we made the decision to focus our efforts on becoming a stronger medical technology company with a patented technology for Class III surgical markets that would enhance the Company’s value and overall market strength. The FDA approval process requires a substantial amount of the Company’s resources and energy so we paused our efforts on sales and marketing to non-Class III markets and our full attention was focused on completing the FDA process and identifying an acquisition/commercial partner candidate. As of the filing date of this Form 10-Q, the FDA review process, which was temporarily held up by the Covid-19 pandemic, is ongoing.
CURRENT EVENTS:
The following developments in the Company’s business have occurred during 2020:
The London based Journal of Wound Care published the Company's submitted article, Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting, in its November 2020 edition. The article highlights the results of the study demonstrating HemoStyp's superiority to Surgicel® Original, the current standard of care produced by Johnson & Johnson Ethicon division.
Our HemoStyp Gauze Products
HemoStyp Hemostatic Gauze is a collagen-like natural substance created from chemically treated cellulose. It is an effective hemostatic agent registered with the FDA to help control bleeding from open wounds and body cavities. The HemoStyp hemostatic material contains no chemical additives, thrombin or collagen, and is hypoallergenic. When the product comes in contact with blood it expands slightly and converts to an adhesive gel that subsequently breaks down into glucose and salts. Because of its benign impact on body tissue and the fact that it simply degrades to non-toxic end products, HemoStyp does not cause significant delay in healing as do certain other hemostatic materials. Labratory testing has shown HemoStyp to be 100% absorbable in the human body in 24 hours or less. A human trial conducted in 2019 and 2020 demonstrated the effectiveness of HemoStyp in vascular, thoracic and abdominal surgical procedures.
THEN THIS MORNING THIS:
United Health Products Announces Leadership Changes
8:05 AM ET 11/24/20 | BusinessWire
HENDERSON, Nev,--(BUSINESS WIRE)--November 24, 2020--
United Health Products, Inc. (OTC: UEEC), ("UHP" or the "company"), developer, manufacturer and marketer of HemoStyp(R), a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent, today announced changes to its senior management team and its Board of Directors.
Douglas Beplate, co-founder of the company and currently Chief Executive Officer and Chairman of the Board of Directors, will be retiring from the day to day management role and will continue as the Chairman. Brian Thom will assume the role of Chief Executive Officer effective December 1, 2020 and then join the Board of Directors on January 1, 2021.
Mr. Thom has been working closely with UHP since 2018 as a consultant and financial advisor. He brings over 20 years of corporate finance experience and a successful track record of helping fast growing companies across a broad range of industries to raise capital and create shareholder value. Over the course of his career he spent a decade with JPMorgan's global Mergers and Acquisitions group and five years leading the Americas Corporate Finance group with Société Générale, a multi-national European investment bank, among other entrepreneurial pursuits. During this time, Mr. Thom played a major role in over 60 M&A and equity placement transactions with an aggregate transaction value in excess of $200 billion.
Mr. Beplate commented: "Brian has spent the past two years working with me and the management team and has consequently developed a deep understanding of UHP's technology and its potential applications across several attractive markets. He has mapped out a clear strategy to transition from our R&D focus to a commercialization phase and I look forward to working closely with Brian to maximize our company's value for an eventual sale or merger at the appropriate time."
Concurrent with this change, Nate Knight, UHP's Chief Financial Officer and a Director, will be retiring after ten years with the company. Kris Heaton will assume the role of Vice President, Finance and serve as principal financial officer. Kris is a CPA who has been working with the company for several years, assisting in preparation of financial statements and SEC filings, and is familiar with UHP's financial circumstances and growth objectives. Kris' accounting and financial expertise will serve UHP well as the company ramps up commercial business operations.
Doug Beplate commented: "Nate has been instrumental in securing the financial resources necessary for the company to advance its R&D and FDA application activities. He leaves the company in good shape and we thank him for his dedication to UHP and its shareholders."
Upon Mr. Knight's retirement from the Board of Directors, Lou Schiliro, UHP's Chief Operating Officer, will be appointed to the Board as a Director.
These leadership changes bring the talent, experience and energy that are necessary to successfully guide the company forward. In anticipation of a successful Class III PMA approval, the management team will pursue a full range of commercial, strategic and capital markets initiatives to facilitate growth of the business and create shareholder value.
Looks like UEEC is prepping for FDA Approval and a potential buyout/merger with someone else, maybe JOHNSON & JOHNSON. The timing is right on. Transitioning from R & D to M & A.
If APPROVED, we see UEEC trading north of $5.00--$10.00. Great spec buy at $1.19.
Regards,
SPORTYNORTY
